Standout Papers

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer 2020 2026 2022 2024343
  1. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer (2020)
    Vicky Makker, Matthew H. Taylor et al. Journal of Clinical Oncology

Immediate Impact

5 by Nobel laureates 2 from Science/Nature 60 standout
Sub-graph 1 of 22

Citing Papers

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy
2025 Standout
2 intermediate papers

Works of Raquel Bratos being referenced

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
2020 Standout
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.
2019
and 1 more

Author Peers

Author Last Decade Papers Cites
Raquel Bratos 105 314 216 211 13 581
Steven DeCesare 140 242 234 251 13 679
Andreas duBois 101 288 396 124 15 701
Albert Steren 89 254 330 251 21 708
Joyce Varughese 77 320 115 116 21 610
Elisabeth Janschek 114 309 171 154 16 637
Melina Shoni 151 124 181 217 22 602
Richard A. Boothby 67 315 283 102 7 585
A. De Jesus Acosta 118 299 103 150 9 513
Sarper Toker 106 326 102 273 10 581
M. Valeria Cáceres 110 350 109 289 11 613

All Works

Loading papers...

Rankless by CCL
2026